临床医生对催化剂治疗麻醉症的偏好:调查和离散选择实验
Anne Marie Morse1, Lois Krahn2, Julie Flygare3
1Geisinger Commonwealth School of Medicine, Geisinger Medical Center, Janet Weis Children's Hospital, Danville, PA, USA.
Advances in therapy
|May 27, 2023
概括
临床医生更喜欢每晚一次剂量用于麻醉治疗,包括立即释放的氧酸盐 (SXB) 和混合盐氧酸盐. 这种偏好是改善患者生活质量和减少焦虑的关键.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻醉症显著影响患者的生活质量 (QoL).
- 目前的氧酸盐治疗 (即时释放的氧酸盐和混合盐氧酸盐) 需要每晚两次剂量.
- 试验中的延长释放氧酸盐可能提供每晚一次的选择.
研究的目的:
- 了解临床医生在麻醉症的不同氧酸盐配方中的偏好.
- 评估临床医生对剂量频率对患者结果的影响的观点.
主要方法:
- 一个基于网络的调查和离散选择实验 (DCE) 被给予100名经验丰富的临床医生治疗麻醉症.
- 临床医生对疾病的影响,对治疗的看法和满意度进行了9分评分.
- DCE评估了包括剂量频率,QoL影响和焦虑减轻在内的属性的偏好.
主要成果:
- 临床医生评价麻醉症对QoL的负面影响很高 (平均值7.7).
- 对目前的氧化剂的有效性和安全性的满意度中等,但对每晚两次剂量的满意度较低 (平均值5.9-6.3).
- 剂量频率是临床医生选择中最关键的属性,每晚一次的剂量强烈优先于每晚两次.
结论:
- 临床医生显著偏爱每晚一次的oxybate剂量表.
- 这种偏好在整体治疗选择,改善患者生活质量和减少患者焦虑方面是一致的.
- 每晚服用一次的剂量是未来在麻醉症管理中选择氧酸盐治疗的关键因素.
相关概念视频
Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
Narcolepsy
158
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
158
Management of Insomnia
287
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
287
Sedatives and Hypnotics Drugs: Miscellaneous Agents
205
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
205
CNS Depressants: Barbiturates and Benzodiazepines
359
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
359
Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221


